QT interval prolongation and the risk of torsades de pointes: essentials for clinicians

@article{Trinkley2013QTIP,
  title={QT interval prolongation and the risk of torsades de pointes: essentials for clinicians},
  author={K. Trinkley and Robert Lee Page and Hoang Lien and Kevin Yamanouye and J. Tisdale},
  journal={Current Medical Research and Opinion},
  year={2013},
  volume={29},
  pages={1719 - 1726}
}
Abstract Objective: QT interval prolongation signifies an increased risk of the life-threatening arrhythmia torsades de pointes (TdP). The purpose of this paper is to review the diverse methods for assessing and monitoring the risk of TdP, discuss risk factors for TdP, and recommend interventions that may mitigate the risk of TdP. Methods: A non-systematic search of PubMed (through March 2013) was conducted to determine the optimal approach to assessing and monitoring QT interval, prevention of… Expand
Managing drug-induced QT prolongation in clinical practice
TLDR
To support clinicians, who are likely to prescribe such medicines in their daily practice, a simple algorithm is developed to help guide clinical management in patients who are at risk of QT prolongation/TdP, those exposed to QT-prolonging medication or have QT extension. Expand
Drug-Induced QT Interval Prolongation: Mechanisms, Risk Factors, Genetics and Clinical Management
TLDR
The purpose of this article is to review the underlying mechanisms of QTP, risk factors and genetics of DI-QTP, how to measurement of QT interval and treatment of acquired LQTS, and drugs that have been associated with QTP and TdP. Expand
Drug-induced QT interval prolongation and torsades de pointes
  • J. Tisdale
  • Medicine
  • Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC
  • 2016
TLDR
P is a life-threatening arrhythmia associated with prolongation of the corrected QT (QTc) interval on the electrocardiogram and treatment consists of discontinuation of the offending drug(s), correction of electrolyte abnormalities and administration of intravenous magnesium sulfate. Expand
Identification of Patients At-Risk of QT Interval Prolongation during Medication Reviews: A Missed Opportunity?
TLDR
There is a need to improve knowledge and awareness of this topic among pharmacists performing medication reviews, and Pharmacists’ recommendations, when present, were focused on drugs with known risk of QT interval prolongation, rather than patients’ additional risk factors. Expand
Co-Prescription of QT-Interval Prolonging Drugs: An Analysis in a Large Cohort of Geriatric Patients
TLDR
A considerable proportion of QT-drugs with higher risk only could be detected by using more than one classification-system, and local adaption of international classifications can improve identification of patients at risk. Expand
Predictive Analytics for Identification of Patients at Risk for QT Interval Prolongation: A Systematic Review
TLDR
The effectiveness of predictive analytics for identification of patients at risk of drug‐induced QTc interval prolongation and the efficacy of incorporation of predictive Analytics into CDS tools in clinical practice are assessed. Expand
A literature-based algorithm for the assessment, management, and monitoring of drug-induced QTc prolongation in the psychiatric population
TLDR
The literature-based algorithm developed provides a stepped-based approach for the assessment, monitoring, and management of drug-induced QTc prolongation in the psychiatric population and may assist mental health clinicians in the decision-making process when psychiatric patients are prescribed medications known to increase theQTc interval. Expand
Prevalence of QTc Prolongation in Patients with Parkinson’s Disease. Assessment of the Effects of Drugs, Clinical Risk Factors and Used Correction Formula
TLDR
LongerQTc in PD patients was associated with older age, male sex and QTc-prolonging drugs regardless of the used formula, and was also significantly affected by the heart rate. Expand
QT prolongation and cardiac toxicity of new tuberculosis drugs in Europe: a Tuberculosis Network European Trialsgroup (TBnet) study
TLDR
Few cardiac arrhythmias and no fatalities were observed in MDR-TB patients treated with bedaquiline and delamanid in treatment centres of the Tuberculosis Network European Trialsgroup (TBnet), a clinical research collaboration of the European Respiratory Society, within the World Health Organization Europe region. Expand
QTc Prolongation and Risk of Torsades de Pointes in Hospitalized Pediatric Oncology Patients.
TLDR
The prevalence of torsades in hospitalized pediatric oncology patients was low, although the risk was significantly greater in patients with a QTc of ≥500 ms, and routine monitoring of electrocardiograms and electrolytes is essential in patientswith risk factors predisposing to QTC prolongation. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 39 REFERENCES
Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes.
Drug-induced long QT syndrome is characterized by a prolonged corrected QT interval (QTc) and increased risk of a polymorphic ventricular tachycardia known as torsade de pointes (TdP). We reviewExpand
Torsade de Pointes Due to Noncardiac Drugs: Most Patients Have Easily Identifiable Risk Factors
TLDR
It is suggested that almost all patients with torsade de pointes secondary to noncardiac drugs have risk factors that can be easily identified from the medical history before the initiation of therapy with the culprit drug. Expand
Prevalence of QT Interval Prolongation in Patients Admitted to Cardiac Care Units and Frequency of Subsequent Administration of QT Interval-Prolonging Drugs
TLDR
The aim of this study was to determine the prevalence of Bazett’s-corrected QT (QTc) interval prolongation upon admission to cardiac units and the proportion of patients presenting with QTc intervals prolongation who are subsequently administered QT interval-prolonging drugs during hospitalization. Expand
Development and Validation of a Risk Score to Predict QT Interval Prolongation in Hospitalized Patients
TLDR
A risk score using easily obtainable clinical variables predicts patients at highest risk for QTc interval prolongation and may be useful in guiding monitoring and treatment decisions. Expand
Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation.
Cardiac arrest due to torsade de pointes (TdP) in the acquired form of drug-induced long-QT syndrome (LQTS) is a rare but potentially catastrophic event in hospital settings. Administration of aExpand
Drug induced QT prolongation and torsades de pointes
TLDR
In 1966, Francois Dessertenne described a specific electrocardiographic form of polymorphic ventricular tachycardia, which he termed “torsades de pointes” (TdP) and, until recently, there has been considerable conjecture as to the pathophysiology of this arrhythmia. Expand
QTc Interval Screening in Methadone Treatment
TLDR
An expert panel was convened to address the cardiac effects of methadone, and found that a consensus document was warranted on QTc interval screening. Expand
QT interval and antidepressant use: a cross sectional study of electronic health records
TLDR
A modest prolongation of QT interval with citalopram was confirmed and additional antidepressants with similar observed risk were identified, and Pharmacovigilance studies using electronic health record data may be a useful method of identifying potential risk associated with treatments. Expand
Cardiac safety, drug-induced QT prolongation and torsade de pointes (TdP).
  • J. Ritter
  • Medicine
  • British journal of clinical pharmacology
  • 2012
TLDR
Not only do drugs differ in their potential to cause TdP, but several patient factors also strongly influence the risk, and one of the strongest of these is female sex, which is lower in women than in men. Expand
The Long QT Syndrome: Prospective Longitudinal Study of 328 Families
TLDR
Among 232 probands and 1,264 family members with prospective follow-up, three factors made significant independent contributions to the risk of subsequent syncope or probable LQTS-related death before age 50 years, whichever occurred first (Cox hazard ratio; 95% confidence limits). Expand
...
1
2
3
4
...